<DOC>
	<DOC>NCT00843193</DOC>
	<brief_summary>Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study</brief_summary>
	<brief_title>Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma</brief_title>
	<detailed_description>A Multi-Centre, Multi-conutry, Randomized, Double-Blind (Subject, Investigator), Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>history of asthma for ≥ 6 months taking inhaled corticosteroids nonsmoking Baseline (prebronchodilator) FEV1 3580% predicted at screening. Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline after nebulised salbutamol or albuterol. symptomatic according to the ACQ7 Unstable severe asthma Recent respiratory illness Presence of other respiratory disease or chronic pulmonary condition other than asthma Treatment with omalizumab within 4 months of study Recent gastrointestinal or respiratory parasitic infestation History of severe allergy to food or drugs Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Asthma control questionnaire</keyword>
</DOC>